RESUMO
Fundamento e objetivos: A cardiomiopatia cirrótica tem sido usada para descrever a disfunção cardíaca crônica em pacientes cirróticos sem doença cardíaca estrutural prévia. Além disso, o prolongamento do intervalo QT é uma das alterações cardíacas mais importantes relacionadas à cirrose. Estudos prévios sugerem que o prolongamento QT está associado com uma taxa de mortalidade mais alta em pacientes cirróticos. O objetivo deste estudo foi analisar intervalos QTs segundo a gravidade da cirrose, medida pela classificação Child-Plugh. Materiais e métodos: Em um estudo transversal, um total de 67 pacientes com cirrose não alcoólica submeteu-se à avaliação clínica e eletrocardiográfica. A gravidade da cirrose foi classificada de acordo com o escore Child-Pugh. O intervalo QT foi medido por um eletrocardiograma de 12 derivações. Resultados: Os intervalos QTs foram mais longos em pacientes no grupo Child-Plugh C que nos grupos Child-Pugh A e B (459 ± 33 vs 436 ± 25 e 428 ± 34 ms, respectivamente, p = 0,004). Houve uma correlação positiva entre o intervalo QT e o escore Child-Pugh em indivíduos com escore Child-Pugh ≥ 7 (r = 0,50; p < 0,05) e intervalos QT ≥ 440 ms (r = 0,46, p < 0,05). Conclusão: O presente estudo mostrou que pacientes com cirrose Child-Plugh C apresentam intervalos QTs mais longos, o que reforçou a relação entre a gravidade da cirrose e achados eletrocardiográficos da cardiomiopatia cirrótica. Além disso, esse resultado foi encontrado em pacientes sem sintomas cardíacos, o que destacou a importância de um método simples e não invasivo, como o eletrocardiograma, para identificar pacientes cirróticos com cardiomiopatia
Background and aims: Cirrhotic cardiomyopathy has been used to describe chronic cardiac dysfunction in cirrhotic patients with no previous structural heart disease. Additionally, QT prolongation is one of the most important cardiac alterations related to cirrhosis. Previous studies suggest that QT prolongation is associated with a higher mortality rate among cirrhotic patients. The aim of this study was to analyze QT intervals according to cirrhosis severity as measured by the Child-Pugh classification. Materials and methods: In a cross-sectional study, a total of 67 patients with nonalcoholic cirrhosis underwent clinical and electrocardiographic evaluation. Cirrhosis severity was classified according to the Child-Pugh score. The QT interval was measured by a 12-lead electrocardiogram. Results: The QT intervals were longer in patients in the Child-Pugh C group than those in the Child-Pugh A and B groups (459 ± 33 vs 436 ± 25 and 428 ± 34 ms, respectively, p=0.004). There was a positive correlation between the QT interval and the Child-Pugh score in individuals with Child-Pugh scores ≥ 7 (r=0.50, p<0.05) and QT intervals ≥ 440 ms (r=0.46, p<0.05). Conclusion: The present study showed longer QT intervals in patients with Child-Pugh C cirrhosis, which reinforced the relationship between the severity of cirrhosis and electrocardiographic findings of cirrhotic cardiomyopathy. Moreover, this finding emerged in patients with no cardiac symptoms, which highlighted the importance of a simple and noninvasive method (ECG) to identify cirrhotic patients with cardiomyopathy
Assuntos
Humanos , Masculino , Feminino , Eletrocardiografia/métodos , Cirrose Hepática/mortalidade , Síndrome do QT Longo , Análise de Variância , Cardiomiopatias/complicações , Cardiomiopatias/diagnóstico , Estudos Transversais , Estatísticas não ParamétricasRESUMO
Diarrhea is one of the most common symptoms in common variable immunodeficiency, but neurologic manifestations are rare. We presented a 50-year-old woman with recurrent diarrhea and severe weight loss that developed a posterior cord syndrome. Endoscopy found a duodenal villous blunting, intraepithelial lymphocytosis, and lack of plasma cells and magnetic resonance imaging of the spine was normal. Laboratory assays confirmed common variable immunodeficiency syndrome and showed low levels of trace elements (copper and zinc). Treatment was initiated with parenteral replacement of trace elements and intravenous human immunoglobulin and the patient improved clinically. In conclusion, physicians must be aware that gastrointestinal and neurologic disorders may be related to each other and remember to request trace elements laboratory assessment.
RESUMO
Hepatorenal syndrome (HRS) is defined as a failure of renal function, potentially reversible, in patients with liver cirrhosis and ascites. Recently, a component of cardiomyopathy associated with HRS was described, but the use of positive inotropic medicine as part of the treatment of the acute phase has not been extensively evaluated. We report a second case in our hospital of a patient with HRS type I without previous heart disease, with secondary hemodynamic decompensation due to liver disease, in which the abnormalities in systolic function by speckle-tracking echocardiography were observed and could be reversed by the use of inotropes. After partial response to current therapies, the patient presented a clinical and laboratorial response with improvement of renal function after infusion of dobutamine. Clinical studies are needed for the therapy approach to HRS taking into account myocardial dysfunction as a major contributing factor for renal dysfunction.
Assuntos
Humanos , Masculino , Idoso , Anemia Hemolítica/complicações , Anemia Hemolítica/diagnóstico , Próteses Valvulares Cardíacas/efeitos adversos , Valva Aórtica/cirurgia , Insuficiência Cardíaca/fisiopatologia , Rim/fisiopatologia , Valva Mitral/cirurgia , Fatores de Risco , Resultado do TratamentoRESUMO
A cardiomiopatia cirrótica (CMC) é uma disfunção cardíaca crônica que acomete pacientes cirróticos sem doença cardíaca prévia. Trata-se de uma doença inicialmente assintomática que se manifesta em situações de maior demanda metabólica, devido a menor capacidade cardíaca em aumentar seu inotropismo. O diagnóstico é pautado em alterações eletrocardiográficas e ecocardiográficas. Ainda não há tratamento específico para a CMC, sendo instituídas medicações sintomáticas semelhantes ao tratamento da insuficiência cardíaca. Esta revisão tem por objetivo descrever os aspectos fisiopatológicos, clínicos e diagnósticos da CMC, evidenciando as características clínicas, laboratoriais e eletro e ecocardiográficas no rastreio da disfunção cardíaca nos pacientes cirróticos.
Cirrhotic cardiomyopathy (CCM) is a chronic cardiac dysfunction that affects cirrhotic patients without history of heart disease. It is an initially asymptomatic disease that appears in situations of increased metabolic demand due to lower cardiac capacity to increase inotropism. Diagnosis is based on disorders revealed by electrocardiography and echocardiography. There is no specific treatmentfor CCM. Similar symptomatic medications are established to treat heart failure. This review aims to describe the pathophysiological, clinical and diagnostic aspects of CCM, showing the clinical, laboratory, electrocardiographic and echocardiographic characteristics in assessing cardiac dysfunction in cirrhotic patients.
Assuntos
Humanos , Cardiomiopatias/fisiopatologia , Cirrose Hepática/complicações , Cirrose Hepática/fisiopatologia , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/fisiopatologia , Insuficiência Hepática/fisiopatologia , Doença Crônica , Ecocardiografia/métodos , Eletrocardiografia/métodos , Espectroscopia de Ressonância Magnética/métodos , Sistema Renina-Angiotensina , Fatores de RiscoRESUMO
Systemic sclerosis is a complex disease due to the variety of clinical presentations, often superimposed on other conditions, related or not to the connective tissue. We report a 43-year-old Brazilian woman with limited systemic sclerosis and pulmonary symptoms secondary to gastroesophageal reflux disease, with a clinical presentation similar to a diffuse interstitial lung disease. Because of the frequency of interstitial lung injury due to systemic sclerosis, this was an important differential diagnosis, which could be excluded after optimized treatment of reflux disease, with clinical and radiological improvement. Clinical management of patients with collagen diseases requires clinician skills to identify the natural history and understand its nuances. This is a common situation in clinical practice, but with a few discussions in international literature.
RESUMO
OBJECTIVE: Due to the increased availability of effective treatments, patients with systemic lupus erythematosus (SLE) now have longer survival times, and factors involved in cumulative chronic damage in SLE need to be better understood. This study was undertaken to evaluate the relationship between smoking and cumulative chronic damage in SLE patients. METHODS: A cross-sectional study of SLE patients was performed to investigate the possible association between smoking exposure (ever [previous or current, active or secondhand smokers] or never) and cumulative chronic damage as measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). A systematic review of the literature was conducted by cross-searching Medline for the terms lupus and smoking. RESULTS: We enrolled 105 patients with SLE (96% female), with a mean ± SD age of 40.7 ± 11.4 years and a mean followup time of 8.98 years. Of the 105 patients, 74 had an SDI score of 1-10, and 31 had an SDI score of 0. The difference between smoking exposure and no smoking exposure was significant (P = 0.02 by chi-square test in contingency table analysis), and SLE patients who were never exposed to smoking had 0.78 times the risk of progressing toward a cumulative damage status (SDI score of > 0) (95% confidence interval 0.16-0.98) throughout the followup period compared to those who were ever exposed. In the systematic review of the literature, we found only a small number of articles that addressed some aspects of the relationship between smoking exposure and cumulative damage in SLE patients. CONCLUSION: Our findings indicate that smoking exposure is associated with cumulative chronic damage, as determined by the SDI score, in patients with SLE. Smoking exposure may have deleterious effects on lupus morbidity, and more detailed studies of this association are needed.
Assuntos
Lúpus Eritematoso Sistêmico/fisiopatologia , Fumar/epidemiologia , Poluição por Fumaça de Tabaco/estatística & dados numéricos , Adulto , Estudos de Coortes , Estudos Transversais , Feminino , Humanos , Estudos Longitudinais , Lúpus Eritematoso Sistêmico/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Índice de Gravidade de DoençaRESUMO
The Nobel Prize was created by Alfred Nobel. The first prize was awarded in 1901 and Emil Adolf von Behring was the first laureate in medicine due to his research in diphtheria serum. Regarding cardiology, Nobel Prize’s history permits a global comprehension of progress in pathophysiology, diagnosis and therapeutics of various cardiac diseases in last 120 years. The objective of this study was to review the major scientific discoveries contemplated by Nobel Prizes that contributed to cardiology. In addition, we also hypothesized why Carlos Chagas, one of our most important scientists, did not win the prize in two occasions. We carried out a non-systematic review of Nobel Prize winners, selecting the main studies relevant to heart diseaseamong the laureates. In the period between 1901 and 2013, 204 researches and 104 prizes were awarded in Nobel Prize, of which 16 (15%) studies were important for cardiovascular area. There were 33 (16%) laureates, and two (6%) were women. Fourteen (42%) were American, 15 (45%) Europeans and four (13%) were from other countries. There was only one winner born in Brazil, Peter Medawar, whose career was all in England. Reviewing the history of the Nobel Prize in physiology or medicine area made possible to identify which researchers and studies had contributed to advances in the diagnosis, prevention and treatment of cardiovascular diseases. Most winners were North Americans and Europeans, and male.
O Prêmio Nobel foi criado por Alfred Nobel. Os primeiros prêmios foram entregues em 1901, e o primeiro ganhador na área da medicina foi Emil Adolf von Behring, por seus trabalhos com soro antidiftérico. Na cardiologia, o conhecimento da história do Prêmio Nobel ajuda a entender a importância dos avanços fisiopatológicos, diagnósticos e terapêuticos realizados ao longo dos últimos 120 anos. O objetivo do presente estudo foi revisar as principais descobertas científicas contempladas pelo Prêmio Nobel, que contribuíram para avanços no estudo da cardiologia. Além disso, apresentamos a hipótese pela qual Carlos Chagas, um dos nossos mais importantes cientistas, não recebeu o Prêmio Nobel em duas ocasiões. A partir de uma revisão não sistemática sobre os Prêmios Nobel, foram selecionados, entre os laureados, os principais estudos com relevância para as doenças cardíacas. No período entre 1901 e 2013, 204 pesquisadores, em 104 prêmios, foram premiados na categoria Medicina ou Fisiologia, dos quais 16 estudos (15%) tiveram importância na área da cardiologia. Foram 33 (16%) premiados, sendo apenas duas (6%) mulheres. Em relação ao local de nascimento, 14 (42%) eram norte-americanos, 15 (45%) europeus e quatro (13%) de outros países. Apenas um laureado nasceu no Brasil: Peter Medawar, cuja carreira se deu toda na Inglaterra. A revisão da história do Prêmio Nobel na área de medicina ou fisiologia possibilitou identificar pesquisadores e estudos que contribuíram para avanços no diagnóstico, prevenção e tratamento das doenças cardiovasculares. A maioria dos laureados eram norte‑americanos e europeus, e do sexo masculino.
Assuntos
Feminino , História do Século XX , História do Século XXI , Humanos , Masculino , Cardiologia/história , Prêmio Nobel , Pesquisadores/história , Pesquisa Biomédica/história , Doenças Cardiovasculares/históriaRESUMO
The Nobel Prize was created by Alfred Nobel. The first prize was awarded in 1901 and Emil Adolf von Behring was the first laureate in medicine due to his research in diphtheria serum. Regarding cardiology, Nobel Prize's history permits a global comprehension of progress in pathophysiology, diagnosis and therapeutics of various cardiac diseases in last 120 years. The objective of this study was to review the major scientific discoveries contemplated by Nobel Prizes that contributed to cardiology. In addition, we also hypothesized why Carlos Chagas, one of our most important scientists, did not win the prize in two occasions. We carried out a non-systematic review of Nobel Prize winners, selecting the main studies relevant to heart diseaseamong the laureates. In the period between 1901 and 2013, 204 researches and 104 prizes were awarded in Nobel Prize, of which 16 (15%) studies were important for cardiovascular area. There were 33 (16%) laureates, and two (6%) were women. Fourteen (42%) were American, 15 (45%) Europeans and four (13%) were from other countries. There was only one winner born in Brazil, Peter Medawar, whose career was all in England. Reviewing the history of the Nobel Prize in physiology or medicine area made possible to identify which researchers and studies had contributed to advances in the diagnosis, prevention and treatment of cardiovascular diseases. Most winners were North Americans and Europeans, and male.
Assuntos
Cardiologia/história , Prêmio Nobel , Pesquisadores/história , Pesquisa Biomédica/história , Doenças Cardiovasculares/história , Feminino , História do Século XX , História do Século XXI , Humanos , MasculinoRESUMO
Lúpus eritematoso sistêmico (LES) é uma condição autoimune com processo fisiopatológico complexo, no qual sua atividade inflamatória é potencializadora da doença coronariana através de inflamação sistêmica, disfunção endotelial e predisposição à trombose. O acometimento cardiovascular no LES não é critério diagnóstico, sendo considerado somente como dano já estabelecido em longo prazo de doença. O objetivodeste artigo é destacar a importância da visão clínica para a identificação precoce do acometimento cardiovascular no LES. É feita uma análise crítica da abordagem cardiológica no LES, com ênfase nos aspectos clínicos, biomarcadores cardiovasculares e genética e solicitação racional dos exames complementares. Aparticularidade dos pacientes com nefrite lúpica e síndrome do anticorpo antifosfolipídeo também é destacada.A percepção do dano cardíaco subclínico é fundamental para interromper o ciclo de agressão miocárdica e evitar progressão de doença cardíaca.
Systemic lupus erythematosus (SLE) is an autoimmune condition with a complex pathophysiological process in which its inflammatory activity is an enhancer of coronary disease by systemic inflammation, endothelial dysfunction and predisposition to thrombosis. Thecardiovascular involvement in SLE is not a diagnostic criterion and is considered only as damage established in the long-term of the disease. The objective of this study is to highlight the importance of clinical vision for the early identification of cardiovascular involvement in SLE. A critical analysis of the cardiac approach in SLE, with emphasis on clinical aspects, cardiovascular biomarkers and genetics and rational request of additional tests. The particularity of patients with lupus nephritis and antiphospholipid antibodysyndrome is also highlighted. The perception of subclinical cardiac damage is critical for interrupting the cycle of myocardial injury and to avoid progression of heart disease.
Assuntos
Humanos , Doenças Autoimunes/fisiopatologia , Doenças Autoimunes/genética , Doenças Cardiovasculares/fisiopatologia , Doenças Cardiovasculares/mortalidade , Lúpus Eritematoso Sistêmico/fisiopatologia , Lúpus Eritematoso Sistêmico/genética , Brasil/epidemiologia , Doença da Artéria Coronariana , Etnicidade , Inflamação/fisiopatologia , Inflamação/genética , Prevalência , Fatores de RiscoRESUMO
IgG4-related disease (IgG4-RD) encompasses a group of fibroinflammatory conditions recognized in recent times. The main clinical features include variable degrees of tissue fibrosis, tumorlike expansions, perivascular lymphocytic infiltration rich in IgG4-positive plasma cells, and elevated serum IgG4. A case has been reported of an elderly patient with an unexplained unilateral exophthalmia; biopsy was performed and revealed lymphocytic infiltration, suggesting IgG4-RD. High serum levels of IgG4, in association with a good response to steroid therapy and to the exclusion of other diagnoses, confirmed the hypothesis of orbital pseudotumor by IgG4-RD.
RESUMO
The hepatorenal syndrome (HRS) is defined as a potentially reversible kidney failure in patients with cirrhosis and ascites. An association of HRS and cirrhotic cardiomyopathy has been reported recently, but there are no result studies about the use of positive inotropes as part of the acute phase treatment. We report the case of a patient diagnosed with HRS, with high levels of NT pro-BNP, but with normal ejection fraction of the left ventricle, which showed abnormalities in systolic function through speckle tracking in echocardiography, reversible after the infusion of dobutamine. The patient showed clinical and laboratory improvement of his renal function after the infusion of dobutamine. Clinical studies are needed on HRS therapeutic approach taking into account the myocardial dysfunction as a major contributing factor to renal dysfunction.
RESUMO
A anomalia de Ebstein caracteriza-se pela implantação anômala do folheto septal e frequentemente do folheto posterior no interior do ventrículo direito. A síndrome de disfunção ventricular direita é uma forma incomum de apresentação dessa cardiopatia na idade adulta. Relata-se caso de paciente masculino, 41 anos, com admissão por insuficiência cardíaca descompensada após um ano de investigação sem diagnóstico. Discutem-se os aspectos fisiopatológicos e a evolução dos pacientes com anomalia de Ebstein, com ênfase na variabilidade de apresentações clínicas.
Ebstein's anomaly is characterized by the abnormal implantation of the septal leaflet and often the posterior leaflet into the right ventricle. The syndrome of right ventricular dysfunction is an unusual presentation of this disease in adulthood. We report the case of a male patient, 41 years old, admitted with decompensated heart failure after a year of research undiagnosed. We discuss the pathophysiology and outcome of patients with Ebstein's anomaly, with emphasis on the variability of clinical presentations.
La anomalía de Ebstein se caracteriza por la implantación anormal de la valva septal de la válvula tricúspide y con frecuencia de la valva posterior en el interior del ventrículo derecho. El síndrome de disfunción del ventrículo derecho es una inusual presentación de esta enfermedad en la edad adulta. Presentamos el caso de un paciente de sexo masculino de 41 años que ingresó al hospital por insuficiencia cardíaca descompensada después de un año de investigación sin diagnosticar. Se discute la fisiopatología y la evolución de los pacientes con anomalía de Ebstein, con énfasis en la variabilidad de la presentación clínica.
RESUMO
A anomalia de Ebstein caracteriza-se pela implantaþÒo an¶mala do folheto septal e frequentemente do folheto posterior no interior do ventrículo direito. A síndrome de disfunþÒo ventricular direita é uma forma incomum de apresentaþÒo dessa cardiopatia na idade adulta. Relata-se caso de paciente masculino, 41 anos, com admissÒo por insuficiÛncia cardíaca descompensada após um ano de investigaþÒo sem diagnóstico. Discutem-se os aspectos fisiopatológicos e a evoluþÒo dos pacientes com anomalia de Ebstein, com Ûnfase na variabilidade de apresentaþ§es clínicas.(AU)
Ebsteins anomaly is characterized by the abnormal implantation of the septal leaflet and often the posterior leaflet into the right ventricle. The syndrome of right ventricular dysfunction is an unusual presentation of this disease in adulthood. We report the case of a male patient, 41 years old, admitted with decompensated heart failure after a year of research undiagnosed. We discuss the pathophysiology and outcome of patients with Ebsteins anomaly, with emphasis on the variability of clinical presentations.(AU)
La anomalía de Ebstein se caracteriza por la implantación anormal de la valva septal de la válvula tricúspide y con frecuencia de la valva posterior en el interior del ventrículo derecho. El síndrome de disfunción del ventrículo derecho es una inusual presentación de esta enfermedad en la edad adulta. Presentamos el caso de un paciente de sexo masculino de 41 años que ingresó al hospital por insuficiencia cardíaca descompensada después de un año de investigación sin diagnosticar. Se discute la fisiopatología y la evolución de los pacientes con anomalía de Ebstein, con énfasis en la variabilidad de la presentación clínica.(AU)
RESUMO
Physical cardiovascular examination, particularly cardiac auscultation, is one of the most difficult clinical skills for students during their medical training. Studies suggest that the use of technologies such as digital stethoscope increase the accuracy of clinical examination, however, its impact on the teaching of cardiac auscultation for undergraduate students of medicine is not known. The objective is to demonstrate the usefulness of the digital stethoscope compared to traditional methods as a tool in the teaching of auscultatory skills. nterventional, longitudinal, controlled, unicenter and randomized study. Thirty-eight medicine students were enrolled for a cardiovascular semiology course lasting eight weeks. The course program included lectures and bedside practice in Cardiology wards. In the practical lessons, the students were randomized into two groups: 1) (n = 21) digital stethoscope (Littmann® Model 3200, 3M); and 2) (n = 17) conventional stethoscopes. A pre-training evaluation was conducted through a test using the software Heart Sounds®, which was repeated after the course. The average scores were compared by paired T test and unpaired T test. It is observed that, at the end of the course, there was a significantly greater improvement in the group that used the digital stethoscope (51.9%) compared to the group using the conventional stethoscope (29.5%). Short-term interventions for cardiac semiology teaching are able to contribute significantly to improving proficiency in the identification of heart sounds. The use of digital stethoscope proved to be a positive factor in teaching these skills.
Assuntos
Cardiologia/educação , Auscultação Cardíaca/instrumentação , Estetoscópios , Ensino/normas , Interpretação Estatística de Dados , Auscultação Cardíaca/normas , Humanos , Estudos Longitudinais , Estudantes de Medicina , Ensino/métodosRESUMO
Fundamentos: Estudos demonstram a importante prevalência do déficit de vitamina D (vit. D) em pacientes com insuficiência cardíaca com fração deejeção reduzida (ICFER). O déficit de vit. D se relaciona com a piora na qualidade de vida e redução do desempenho funcional. Com o envelhecimento, a insuficiência cardíaca com fração de ejeção normal (ICFEN) tornar-se-á o tipo de insuficiência cardíaca mais comum, com resultados referentes ao prognóstico semelhantes aos da ICFER. Apesar das evidências daação benéfica da vit. D no sistema cardiovascular em pacientes com ICFER, não há estudos clínicos que demonstrem a melhora morfofuncional cardiovascularcom a suplementação de vit.D em pacientes com ICFEN. Objetivo: Demonstrar a melhora da qualidade de vida e função diastólica em pacientes com ICFEN, após suplementação de vit. D. Métodos: E s t u d o p ro s p e c t i v o , d u p l o-c e g o randomizado, placebo controlado, envolvendo 40 pacientes com ICFEN e deficiência de vit. D (25OHD<30ng/mL), por 20 semanas de tratamento. Os pacientes receberão suplementação de 100.000UI decolecalciferol ou placebo no início do estudo e na 10ª semana, sob supervisão médica. Os pacientes serão avaliados por: testes funcionais (timed up and go test e 6 minute walk test), exames laboratoriais, questionário Minnesota Living with Heart Failure, eletrocardiograma e ecoDopplercardiograma, avaliando a função sistólica, a diastólica e o remodelamento ventricular no início doestudo, em 10 semanas e em 20 semanas. Conclusão: O estudo FITNESS avaliará o impacto morfofuncional cardiovascular e na qualidade de vida em 20 semanas na suplementação de colecalciferol em pacientes com ICFEN e déficit de vit. D.
Background: Studies have shown a significant prevalence of vitamin D (Vit. D) deficits in heart failure patients with reduced ejection fraction(HFREF), related to poorer quality of life andreductions in functional performance. With anaging population, heart failure with preserved ejection fraction (HFPEF) will become the most common type of heart failure (HF), with similar results for HFREF predictions. Despite evidence of the beneficial action of vit. D on the cardiovascular system in HFREF patients, there are no clinical s t u d i e s demo n s t r a t i n g c a rd i o v a s c u l a r morphofunctional improvement through vit.D supplementation in HFPEF patients. Objective: To demonstrate improvements in the quality of life and diastolic function for FPEF patients taking vit. D supplements. Methods: Prospective, double-blind, randomized, placebo-controlled study, with 40 patients with HFNEF and vit. D deficiency (25OHD <30ng/mL)for 20 weeks of treatment. Patients will receive supplements of 100,000IU of cholecalciferol (Vit. D3)or placebo at baseline and at 10 weeks under medical supervision. They will be assessed by: functional tests (timed up-and-go test and 6-minute walk test),laboratory examinations, the Minnesota Living with Heart Failure Questionnaire, electrocardiogram, evaluating systolic and diastolic functions and ventricular remodeling at baseline, and at 10 and 20weeks.Conclusion: The FITNESS study will evaluate cardiovascular morphofunctional impacts and effects on the quality of life during 20 weeks of cholecalciferol supplementation in HFPEF patients with vit. D deficits.
Assuntos
Humanos , Deficiência de Vitamina D/complicações , Insuficiência Cardíaca Diastólica/complicações , Insuficiência Cardíaca Diastólica/diagnóstico , Qualidade de Vida/psicologia , Volume Sistólico , Interpretação Estatística de Dados , Estudos ProspectivosRESUMO
A distrofia miotônica tipo 1 (DM1 ou doença de Steinert) é uma doença genética com repercussões multissistêmicas, na qual é comum o paciente buscar diversos especialistas antes da suspeição clínica. O envolvimento cardíaco é uma das características principais da evolução da DM1 e explica, em parte, a menor expectativa de vida dos pacientes. Relata-se caso de paciente masculino, 28 anos, com admissão por insuficiência cardíaca descompensada após oito anos de diagnóstico quando apresentou episódio de síncope secundária a bloqueio atrioventricular total. Sob marca-passo definitivo desde então. Discutem-se os aspectos etiológicos, fisiopatológicos e clínicos da DM1 com ênfase nas manifestações cardiovasculares.
Myotonic Dystrophy type 1 (MD1 or Steinert's Disease) is a genetic syndrome with multissistemic repercussions, and it is usual to the patient to seek for several specialists before clinical suspicion. It is related a case of a 28 years old male patient admitted with congestive heart failure. MD1 has been diagnosed eight years before. At the time of the diagnosis, he presented syncope secondary to Complete Atrioventricular Block. From that time on, he had a permanent pacemaker implanted. Etiological, pathophysiological and clinical aspects of MD1 with emphasis on cardiovascular manifestations are discussed.
La distrofia miotónica tipo 1 (DM1 o enfermedad de Steinert) es un síndrome genético con efectos multisistémicos, siendo común que los pacientes consulten con varios especialistas antes de la sospecha clínica. El compromiso cardíaco es una de las características principales de la evolución de la DM1 y explica, en parte, una menor expectativa de vida de los pacientes. Se presenta el caso de un paciente masculino de 28 años, que ingresó por insuficiencia cardíaca descompensada. Se le había diagnosticado DM1 ocho años antes, al presentar episodios sincopales secundarios a bloqueo aurículo-ventricular completo. A partir de entonces, se le realiza el implante de un marcapasos definitivo. Se discuten los aspectos etiológicos, fisiopatológicos y clínicos de la DM1 con énfasis en las manifestaciones cardiovasculares.
RESUMO
A distrofia miot¶nica tipo 1 (DM1 ou doenþa de Steinert) é uma doenþa genética com repercuss§es multissistÛmicas, na qual é comum o paciente buscar diversos especialistas antes da suspeiþÒo clínica. O envolvimento cardíaco é uma das características principais da evoluþÒo da DM1 e explica, em parte, a menor expectativa de vida dos pacientes. Relata-se caso de paciente masculino, 28 anos, com admissÒo por insuficiÛncia cardíaca descompensada após oito anos de diagnóstico quando apresentou episódio de síncope secundária a bloqueio atrioventricular total. Sob marca-passo definitivo desde entÒo. Discutem-se os aspectos etiológicos, fisiopatológicos e clínicos da DM1 com Ûnfase nas manifestaþ§es cardiovasculares.(AU)
Myotonic Dystrophy type 1 (MD1 or Steinerts Disease) is a genetic syndrome with multissistemic repercussions, and it is usual to the patient to seek for several specialists before clinical suspicion. It is related a case of a 28 years old male patient admitted with congestive heart failure. MD1 has been diagnosed eight years before. At the time of the diagnosis, he presented syncope secondary to Complete Atrioventricular Block. From that time on, he had a permanent pacemaker implanted. Etiological, pathophysiological and clinical aspects of MD1 with emphasis on cardiovascular manifestations are discussed.(AU)
La distrofia miotónica tipo 1 (DM1 o enfermedad de Steinert) es un síndrome genético con efectos multisistémicos, siendo común que los pacientes consulten con varios especialistas antes de la sospecha clínica. El compromiso cardíaco es una de las características principales de la evolución de la DM1 y explica, en parte, una menor expectativa de vida de los pacientes. Se presenta el caso de un paciente masculino de 28 años, que ingresó por insuficiencia cardíaca descompensada. Se le había diagnosticado DM1 ocho años antes, al presentar episodios sincopales secundarios a bloqueo aurículo-ventricular completo. A partir de entonces, se le realiza el implante de un marcapasos definitivo. Se discuten los aspectos etiológicos, fisiopatológicos y clínicos de la DM1 con énfasis en las manifestaciones cardiovasculares.(AU)